Literature DB >> 29077933

Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.

Josie Hayes1, Yao Yu2, Llewellyn E Jalbert3, Tali Mazor1, Lindsey E Jones1, Matthew D Wood4, Kyle M Walsh5, Henrik Bengtsson6,7, Chibo Hong1, Stefan Oberndorfer8, Thomas Roetzer9, Ivan V Smirnov1, Jennifer L Clarke1,10,11, Manish K Aghi1, Susan M Chang1,10, Sarah J Nelson3,12, Adelheid Woehrer9, Joanna J Phillips1,4, David A Solomon4, Joseph F Costello1.   

Abstract

Background: Rare multicentric lower-grade gliomas (LGGs) represent a unique opportunity to study the heterogeneity among distinct tumor foci in a single patient and to infer their origins and parallel patterns of evolution.
Methods: In this study, we integrate clinical features, histology, and immunohistochemistry for 4 patients with multicentric LGG, arising both synchronously and metachronously. For 3 patients we analyze the phylogeny of the lesions using exome sequencing, including one case with a total of 8 samples from the 2 lesions.
Results: One patient was diagnosed with multicentric isocitrate dehydrogenase 1 (IDH1) mutated diffuse astrocytomas harboring distinct IDH1 mutations, R132H and R132C; the latter mutation has been associated with Li-Fraumeni syndrome, which was subsequently confirmed in the patient's germline DNA and shown in additional cases with The Cancer Genome Atlas data. In another patient, phylogenetic analysis of synchronously arising grade II and grade III diffuse astrocytomas demonstrated a single shared mutation, IDH1 R132H, and revealed convergent evolution via non-overlapping mutations in ATRX and TP53. In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second. Conclusions: Each tumor in multicentric LGG cases may arise independently or may diverge very early in their development, presenting as genetically and histologically distinct tumors. Comprehensive sampling of these lesions can therefore significantly alter diagnosis and management. Additionally, somatic IDH1 R132C mutation in either multicentric or solitary LGG identifies unsuspected germline TP53 mutation, validating the limited number of published cases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29077933      PMCID: PMC5892142          DOI: 10.1093/neuonc/nox205

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  40 in total

1.  Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome.

Authors:  Takuya Watanabe; Anne Vital; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2009-04-02       Impact factor: 17.088

2.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

3.  Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Authors:  Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello
Journal:  Science       Date:  2013-12-12       Impact factor: 47.728

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 5.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

6.  Germline p53 gene mutations in subsets of glioma patients.

Authors:  A P Kyritsis; M L Bondy; M Xiao; E L Berman; J E Cunningham; P S Lee; V A Levin; H Saya
Journal:  J Natl Cancer Inst       Date:  1994-03-02       Impact factor: 13.506

7.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

8.  Reducing INDEL calling errors in whole genome and exome sequencing data.

Authors:  Han Fang; Yiyang Wu; Giuseppe Narzisi; Jason A O'Rawe; Laura T Jimenez Barrón; Julie Rosenbaum; Michael Ronemus; Ivan Iossifov; Michael C Schatz; Gholson J Lyon
Journal:  Genome Med       Date:  2014-10-28       Impact factor: 11.117

9.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

Authors:  F Favero; T Joshi; A M Marquard; N J Birkbak; M Krzystanek; Q Li; Z Szallasi; A C Eklund
Journal:  Ann Oncol       Date:  2014-10-15       Impact factor: 32.976

10.  ClinVar: public archive of relationships among sequence variation and human phenotype.

Authors:  Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

View more
  11 in total

Review 1.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

2.  Prognostic significance of ARL9 and its methylation in low-grade glioma.

Authors:  Yutang Tan; Suojun Zhang; Qungen Xiao; Junwen Wang; Kai Zhao; Weihua Liu; Kuan Huang; Weidong Tian; Hongquan Niu; Ting Lei; Kai Shu
Journal:  Genomics       Date:  2020-08-31       Impact factor: 5.736

3.  METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas.

Authors:  Xin Shu; Xinquan Li; Xiaochen Xiang; Qiang Wang; Qingming Wu
Journal:  Aging (Albany NY)       Date:  2021-08-26       Impact factor: 5.682

4.  Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.

Authors:  Zhiqun Bai; Xuemei Wang; Zhen Zhang
Journal:  Front Genet       Date:  2022-02-25       Impact factor: 4.599

5.  Dissecting and analyzing the Subclonal Mutations Associated with Poor Prognosis in Diffuse Glioma.

Authors:  Ming Bai; Xiaolong Wang; Huixue Zhang; Jianjian Wang; Gaysina Lyaysan; Si Xu; Kuo Tian; Tianfeng Wang; Jie Li; Na Wang; Xiaoyu Lu; Xiaoming Zhang; Lihua Wang
Journal:  Biomed Res Int       Date:  2022-04-18       Impact factor: 3.246

Review 6.  Multicentric Glioma: An Ideal Model to Reveal the Mechanism of Glioma.

Authors:  Yong Yan; Wei Dai; Qiyong Mei
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

7.  Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features.

Authors:  Emily A Sloan; Stephanie Hilz; Rohit Gupta; Cathryn Cadwell; Biswarathan Ramani; Jeffrey Hofmann; Cassie N Kline; Anu Banerjee; Alyssa Reddy; Nancy Ann Oberheim Bush; Susan Chang; Steve Braunstein; Edward F Chang; Corey Raffel; Nalin Gupta; Peter P Sun; John Y H Kim; Gregory Moes; Elizabeth Alva; Rong Li; Carol S Bruggers; Mouied Alashari; Cynthia Wetmore; Shipra Garg; Megan Dishop; Jessica Van Ziffle; Courtney Onodera; Patrick Devine; James P Grenert; Julieann C Lee; Joanna J Phillips; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Mitchel S Berger; Joseph F Costello; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2020-03-10       Impact factor: 15.887

8.  Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases.

Authors:  Jo-Heon Kim; Woo-Youl Jang; Tae-Young Jung; Shin Jung; Kyung-Keun Kim; Hyung-Seok Kim; Eun-Hee Kim; Min-Cheol Lee; Kyung-Sub Moon; Kyung-Hwa Lee
Journal:  Front Oncol       Date:  2019-08-27       Impact factor: 6.244

9.  Synchronous supratentorial and infratentorial oligodendrogliomas with incongruous IDH1 mutations, a case report.

Authors:  Alexander H C W Agopyan-Miu; Matei A Banu; Michael L Miller; Christopher Troy; Gunnar Hargus; Peter Canoll; Tony J C Wang; Neil Feldstein; Aya Haggiagi; Guy M McKhann
Journal:  Acta Neuropathol Commun       Date:  2021-09-29       Impact factor: 7.801

Review 10.  Genetic syndromes predisposing to pediatric brain tumors.

Authors:  Sameer Farouk Sait; Michael F Walsh; Matthias A Karajannis
Journal:  Neurooncol Pract       Date:  2021-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.